title: Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells.
abstract: Replication-competent adenovirus armed with therapeutic tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene has been shown to sensitize cancer cells to chemotherapy and radiotherapy. However, the synergistic antitumor effect of replication-competent adenovirus expressing TRAIL and the cytotoxic chemotherapy in bladder cancer remains to be determined. Bladder cancer T24 cells or mouse tumor xenografts were infected with replication-competent adenovirus armed with human TRAIL (ZD55-TRAIL) alone or in combination with gemcitabine. The mRNA and protein levels of TRAIL were determined by "Reverse transcription polymerase chain reaction" and Western blotting, respectively. Cell viability was tested by CCK8 assay. Tumor growth in the mice was monitored every week by measuring tumor size. Cell apoptosis was detected by Annexin V-FITC staining and TUNEL assay. We found that adenovirus ZD55-TRAIL efficiently replicated both in cultured bladder cancer T24 cells and T24 mouse tumor xenograft as demonstrated by the overexpression of TRAIL and E1A. Gemcitabine did not affect the expression of TRAIL. In cultured T24 cells, ZD55-TRAIL enhanced the growth inhibitory effects of gemcitabine, accompanied by increased apoptosis. Similarly, ZD55-TRAIL synergistically enhanced the antitumor effect and induction of apoptosis following gemcitabine treatment in mouse T24 xenografts. In conclusion, replicative adenovirus armed with TRAIL synergistically potentiates the antitumor effect of gemcitabine in human bladder cancer. Our study provides the basis for the development of ZD55-TRAIL in combination with conventional chemotherapy for the treatment of bladder cancer.
authors.affiliation: Department of Urology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, 221000, China.
authors.forename: Lijun
authors.initials: L
authors.lastname: Mao
authors.forename: Chunhua
authors.initials: C
authors.lastname: Yang
authors.forename: Liantao
authors.initials: L
authors.lastname: Li
authors.forename: Lanzhou
authors.initials: L
authors.lastname: Nai
authors.forename: Li
authors.initials: L
authors.lastname: Fan
authors.forename: Junqi
authors.initials: J
authors.lastname: Wang
authors.forename: Wang
authors.initials: W
authors.lastname: Li
authors.forename: Rumin
authors.initials: R
authors.lastname: Wen
authors.forename: Jiacun
authors.initials: J
authors.lastname: Chen
authors.forename: Junnian
authors.initials: J
authors.lastname: Zheng
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D015316:Genetic Therapy; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000235:genetics*; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*; D014779:Virus Replication; D023041:Xenograft Model Antitumor Assays; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D053221:TNF-Related Apoptosis-Inducing Ligand; D003841:Deoxycytidine; D000093542:Gemcitabine